Cisplatin may be a valid alternative approach in ovarian carcinoma with carboplatin hypersensitivity. Report of three cases

Massimo Libra, Roberto Sorio, Angela Buonadonna, Massimiliano Berretta, Peter Stefanovski, Giuseppe Toffoli, Giovanna Mazzaglia, Nicoletta Cordani, Franca Stivala, Mauro Boiocchi

Research output: Contribution to journalArticle

Abstract

Platinum-based therapy is considered the standard treatment for patients with advanced ovarian cancer. Carboplatin has a more favorable toxicity profile than cisplatin; however, hypersensitivity reactions to carboplatin have been reported occasionally. We reviewed 112 cases of ovarian cancer treated with carboplatin at our institute to identify the hypersensitivity reactions to this chemotherapeutic agent. Hypersensitivity reactions were documented in nine cases (8%). No deaths occurred, but the reactions were judged severe in three of the 112 patients (2.6%). In our own experience with patients showing idiosyncrasy to carboplatin we observed successful resolution after retreatment with cisplatin. Since patients who relapse after initial treatment with carboplatin often respond to it a second time, it is important to continue this treatment.

Original languageEnglish
Pages (from-to)311-313
Number of pages3
JournalTumori
Volume89
Issue number3
Publication statusPublished - May 2003

Keywords

  • Carboplatin
  • Hypersensitivity reactions
  • Ovarian cancer

ASJC Scopus subject areas

  • Cancer Research

Fingerprint Dive into the research topics of 'Cisplatin may be a valid alternative approach in ovarian carcinoma with carboplatin hypersensitivity. Report of three cases'. Together they form a unique fingerprint.

  • Cite this